On December 6, 2024 EpimAb Biotherapeutics, a global clinical stage biotechnology company specializing in the development of bispecific antibodies, reported the acceptance of a late-breaking abstract featuring our novel BCMA targeted T cell engager (TCE) EMB-06 (CND106) as an oral presentation at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in San Diego, California to be held between December 7-10, 2024 (Press release, EpimAb Biotherapeutics, DEC 6, 2024, View Source [SID1234654055]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This presentation will highlight the full Phase I clinical results for EMB-06 (CND106), a novel BCMA targeting TCE designed with an optimized efficacy and safety profile, in relapsed or refractory multiple myeloma patients. EpimAb recently granted the exclusive rights to develop and commercialize EMB-06 (CND106) outside of Greater China to Candid Therapeutics. The oral presentation details are as follows:
Title: A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody EMB-06 in Relapsed or Refractory Multiple Myeloma
Session Date: December 8
Session Time: 10:45 – 11:00AM local time
Location: Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)
Presentation number: 498
"We are very pleased to share the full results of the EMB-06 FIH study as an oral presentation at the ASH (Free ASH Whitepaper) Annual Conference, and we believe the data highlights EMB-06’s differentiated efficacy and safety profile in multiple myeloma patients," said Dr. Chengbin Wu, Founder and CEO of EpimAb. "The results of this study also provide validation of our TCE technology platform and we will further leverage this expertise to advance novel therapies for diseases with significant unmet need."
About EMB-06
EMB-06 is a novel 2+2 BCMA×CD3 T-cell engaging bispecific antibody discovered using EpimAb’s proprietary CD3 panel and bispecific platforms. Importantly, this molecule has demonstrated lower levels of cytokine release in preclinical and clinical studies.